| Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis P Farci, T Roskams, L Chessa, G Peddis, AP Mazzoleni, R Scioscia, ... Gastroenterology 126 (7), 1740-1749, 2004 | 383 | 2004 |
| Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome P Farci, R Strazzera, HJ Alter, S Farci, D Degioannis, A Coiana, G Peddis, ... Proceedings of the National Academy of Sciences 99 (5), 3081-3086, 2002 | 274 | 2002 |
| Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B P Lampertico, M Viganò, GG Di Costanzo, E Sagnelli, M Fasano, ... Gut 62 (2), 290-298, 2013 | 157 | 2013 |
| Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy MG Carta, MC Hardoy, A Garofalo, E Pisano, V Nonnoi, G Intilla, G Serra, ... Clinical Practice and Epidemiology in Mental Health 3, 1-4, 2007 | 137 | 2007 |
| Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course … R Littera, M Campagna, S Deidda, G Angioni, S Cipri, M Melis, D Firinu, ... Frontiers in immunology 11, 605688, 2020 | 123 | 2020 |
| Real-world experience with obeticholic acid in patients with primary biliary cholangitis D D’Amato, A De Vincentis, F Malinverno, M Viganò, D Alvaro, M Pompili, ... JHEP Reports 3 (2), 100248, 2021 | 62 | 2021 |
| Treatment of chronic hepatitis D P Farci, L Chessa, C Balestrieri, G Serra, ME Lai Journal of viral hepatitis 14, 58-63, 2007 | 57 | 2007 |
| Association of chronic hepatitis C with recurrent brief depression MG Carta, J Angst, MF Moro, G Mura, MC Hardoy, C Balestrieri, L Chessa, ... Journal of affective disorders 141 (2-3), 361-366, 2012 | 55 | 2012 |
| Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, ... Hepatology 66 (6), 1814-1825, 2017 | 49 | 2017 |
| Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network LA Kondili, GB Gaeta, MR Brunetto, A Di Leo, A Iannone, TA Santantonio, ... PLoS One 12 (10), e0185728, 2017 | 48 | 2017 |
| Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection R Littera, L Chessa, S Deidda, G Angioni, M Campagna, S Lai, M Melis, ... PloS One 16 (8), e0255608, 2021 | 47 | 2021 |
| Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? LA Kondili, S Robbins, S Blach, I Gamkrelidze, AL Zignego, MR Brunetto, ... Liver International 38 (12), 2190-2198, 2018 | 47 | 2018 |
| Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV A Karampatou, X Han, LA Kondili, G Taliani, A Ciancio, F Morisco, ... Journal of Hepatology 68 (1), 33-41, 2018 | 44 | 2018 |
| Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management S Deidda, L Tora, D Firinu, S Del Giacco, M Campagna, F Meloni, G Orru, ... Expert Review of Gastroenterology & Hepatology 15 (1), 41-50, 2021 | 38 | 2021 |
| Exploring the role of killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis R Littera, L Chessa, S Onali, F Figorilli, S Lai, L Secci, G La Nasa, ... PLoS One 11 (1), e0146086, 2016 | 31 | 2016 |
| Add‐on peginterferon alfa‐2a to nucleos (t) ide analogue therapy for Caucasian patients with hepatitis B ‘e’antigen‐negative chronic hepatitis B genotype D P Lampertico, MR Brunetto, A Craxì, GB Gaeta, M Rizzetto, A Rozzi, ... Journal of Viral Hepatitis 26 (1), 118-125, 2019 | 30 | 2019 |
| Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin C Cauli, G Serra, L Chessa, C Balestrieri, R Scioscia, ME Lai, P Farci Haematologica 91 (6_Suppl), ECR26-ECR26, 2006 | 30 | 2006 |
| Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: a prospective, observational, controlled study MG Orrù, A Baita, R Sitzia, A Costa, E Muntoni, S Landau, L Chessa, ... Epidemiology and Psychiatric Sciences 14 (3), 145-153, 2005 | 27 | 2005 |
| Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology G D’Amico, L Maruzzelli, A Airoldi, I Petridis, G Tosetti, A Rampoldi, ... Journal of Hepatology 75 (6), 1355-1366, 2021 | 23 | 2021 |
| Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a … S Petta, M Marzioni, P Russo, A Aghemo, A Alberti, A Ascione, A Antinori, ... The Lancet Gastroenterology & Hepatology 2 (6), 427-434, 2017 | 23 | 2017 |
